Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Panobinostat and sorafenib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Sorafenib may also stop the growth of liver cancer by
blocking blood flow to the tumor.
PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when
given together with sorafenib in treating patients with liver cancer that is metastatic
and/or cannot be removed by surgery.